Archive for November, 2019

Harneys received several awards at BVI Financial Services Gala

Saturday, November 30th, 2019

BVI law firm Harneys was named Corporate Service Provider of the Year, Litigation Practice of the Year, and Tech Savvy Firm of the Year, at the BVI Financial Services Gala Awards Dinner which was held on 28 November 2019 to celebrate the 35th anniversary of the BVI International Business Companies Act. Also, the firm got Best Corporate Social Responsibility award, and was recognised for its lifetime service to the BVI.

Harneys BVI Managing Partner Tanya Cassie-Parker said in her comments: “Thank you BVI Financial Services Week Committee for organizing this event in recognition of those that have helped set the standard for legal and financial services in the BVI. Our award wins demonstrate the strong foundation and community ties that Harneys has in the BVI. We are proud to be the first legal practice established in the BVI, and we continue to strive for excellence and innovation in the financial services industry.”

AgeX Therapeutics and its BVI-registered investor Juvenescence Ltd. announced publication of paper on the engineering of universal cells

Saturday, November 2nd, 2019

Juvenescence Ltd., BVI-registered science company developing technologies to treat aging, and AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, announced the publication of a new paper in the scientific journal Regenerative Medicine. The published paper is on the strategies of engineering of allogeneic cells to be hypoimmunogenic (universal), so as not to produce an immune response. Also, the paper presents previously unpublished observation in vivo on allogeneic human stem cells (hPSCs).

The leading author of the paper is Dr. Nafees Malik, Chief Operating Officer at AgeX and Head of Cell & Gene Therapy at Juvenescence, which is a major investor in AgeX. His co-authors on the paper are Gregory Bailey, MD, Chairman of the Board of Directors of AgeX and CEO of Juvenescence; Annalisa Jenkins, MBBS, FRCP, who serves on the Board of Directors of AgeX; and Jim Mellon, Chairman of Juvenescence.

Dr Malik said in his comments on the publication: “This is a huge area of focus for us at AgeX, via our UniverCyte technology platform. In support of our own research and as a service to the overall field, we decided to put together this paper, analyzing all the leading strategies to engineer universal cells and encapsulating them in one paper.”